New AMD3100 derivatives for CXCR4 chemokine receptor targeted molecular imaging studies: synthesis, anti-HIV-1 evaluation and binding affinities.

@article{Poty2015NewAD,
  title={New AMD3100 derivatives for CXCR4 chemokine receptor targeted molecular imaging studies: synthesis, anti-HIV-1 evaluation and binding affinities.},
  author={Sophie Poty and Pauline D{\'e}sog{\`e}re and Christine Goze and Fr{\'e}d{\'e}ric Boschetti and Thomas D'huys and Dominique Schols and Christopher Cawthorne and Stephen J Archibald and Helmut R Ma{\"e}cke and Franck Denat},
  journal={Dalton transactions},
  year={2015},
  volume={44 11},
  pages={
          5004-16
        }
}
CXCR4 is a target of growing interest for the development of new therapeutic drugs and imaging agents as its role in multiple disease states has been demonstrated. AMD3100, a CXCR4 chemokine receptor antagonist that is in current clinical use as a haematopoietic stem cell mobilising drug, has been widely studied for its anti-HIV properties, potential to inhibit metastatic spread of certain cancers and, more recently, its ability to chelate radiometals for nuclear imaging. In this study, AMD3100… CONTINUE READING